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Background. Angiotensin-2 type-1 receptor antagonists not are only antihypertensive drugs but also can inhibit VEGF production.
We hypothesised that adding telmisartan to sunitinib could potentiate the antiangiogenic effects.Material and Methods. 786-O cell
lineswere injected in nudemice.After tumor development,micewere divided into 4 groups: the firstwas the control group (DMSO),
the second group was treated with sunitinib alone, the third group was treated with telmisartan alone, and the fourth group was
treated with the combination. Drugs were orally administered every day for four weeks. Animals were sacrificed after treatment.
Blood and tumor tissues were collected for analysis by immunohistochemistry, Western Blot, and ELISA methods. Results. All
animals developed a ccRCC and ten in each group were treated. Using a kinetic model, tumors tended to grow slower in the
combination group compared to others (𝑃 = 0.06). Compared to sunitinib alone, the addition of telmisartan significantly increased
tissue necrosis (𝑃 = 0.038). Central microvascular density decreased (𝑃 = 0.0038) as well as circulating VEGF (𝑃 = 0.003).
There was no significant variation in proliferation or apoptosis markers. Conclusion. The combination of sunitinib and telmisartan
revealed an enhancement of the blockage of the VEGF pathway on renal tumor resulting in a decrease in neoangiogenesis and an
increase in necrosis.
1. Introduction
Clear cell renal cell carcinoma (ccRCC) represents almost
70% of renal cancers and 3% of malignant tumours in adults.
Distant metastases are present in 20% of the cases, and 30%
of the patients will develop metastases during their natural
history [1]. One of the bad prognostic factors for this tumour
is a high vascular endothelial growth factor (VEGF) con-
centration, which stimulates neoangiogenesis [2]. During the
last years, new antiangiogenic treatments targeting tyrosine
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kinase receptors like VEGF receptors have improved patients’
survival [3, 4]. Nevertheless, many patients are likely to
develop cardiac (hypertension or cardiac failure) or renal side
effects (proteinuria and thrombotic microangiopathy), com-
pelling them to reduce or stop these treatments. However,
hypertension development could predict a good response to
antiangiogenic therapies [5, 6].
Angiotensin II is the active peptide of the Renin-
Angiotensin System (RAS). It is a major regulator of blood
pressure and cardiovascular homeostasis. Its biological effects
are mainly mediated through two types of receptors: AT1-
R and AT2-R, and most physiological effects have been
attributed to AT1-R stimulation. Angiotensin II has been
shown to play a role in different pathological situations
involved in tissue remodelling like cardiac hypertrophy,
development, or wound healing and also in cancers [7].
In addition, several experimental models recently sug-
gested that angiotensin II could be involved in cancer devel-
opment and progression [8, 9] and that RAS blockage by AT1-
R antagonists or Angiotensin converting enzyme inhibitors
(ACE-Is) could be useful in cancer therapy [10]. We therefore
hypothesized that such combination could be tested in
ccRCC so that AT1-R antagonists could potentiate the effects
of tyrosine kinase inhibitors. We also recently demonstrated
that AT1-R was overexpressed in ccRCC with high Fuhrman
grade and that this overexpression was correlated to patients’
survival [11]. These data lead us to suppose that AT1-R
blockers could have antiangiogenic and/or antiproliferative
and/or proapoptotic properties in ccRCC treatment.
The objective of this study was to evaluate the impact
of one AT1-R blocker, telmisartan, alone or in combination
with one tyrosine kinase inhibitor (TKI), sunitinib, on ccRCC
from a macroscopic to a biological perspective.
2. Material and Methods
2.1. Materials. Sunitinib was generously supplied by Pfizer
(SU-11248 AKA PF-2783926-41, Pfizer, USA). Telmisartan
and DMSO were from Sigma-Aldrich, USA.
2.2. Murine Xenograft Model of ccRCC and Treatments. The
scientific project got all permissions from an ethical com-
mittee, which had a full description of the project, to ensure
minimum pain among the animals (Rennes University: R-
2010-CV-01 and R-2011-CV-01). All mice were maintained
according to the guide for the care and use of laboratory
animals.
Forty female nude athymic BALB/c mice (Janvier Labo-
ratory, France) between 6 and 8 weeks were injected with 107
cells 786-O (Human commercial ccRCC cells lines, ATCC,
USA) subcutaneously in the left flank as previously described
[12].
Mice were weighed and blood pressure was measured by
a plethysmographic and noninvasive device (CODA STAN-
DARD MONITOR, Emka Technologies, USA) once a week
and also during all of the duration of the experiment. The
growth of tumor xenografts was monitored once a week by
caliper measurement of length (a), width (b), and thickness
(c). Tumor volumes were calculated using the formula (a × b
× c) × 0.5236.
Five weeks after tumor cell injection, mice were divided
into 4 groups of 10 mice according to the following plan: the
first group comprising 10 untreated mice used as a control
group (DMSO, injection), the second group was composed
of 10 mice treated with sunitinib alone (40mg/kg/d), the
third group included 10 mice treated with ARA-2 alone
(telmisartan 5mg/kg/d), and the fourth consisted of 10 mice
treated with the combination of sunitinib (40mg/kg/d) and
ARA-2 (telmisartan 5mg/kg/d). Sunitinib or telmisartan
powders were dissolved in pure DMSO, then diluted in a
1% water solution, and sonicated. Previous studies showed
that the bioavailability and the metabolisation of sunitinib
were similar for mouse and human allowing us to treat mice
with 40mg/kg/d [13]. Telmisartan was delivered at 5mg/kg/d
according to previous studies [14]. At the end of the 4-week
treatments, mice were anesthetized 24 hours after the last
drug administration with a solution of ketamine (Imalgene
1000, Merial, France) and xylazine 2% (Rampun 2%, Bayer,
Germany) administered subcutaneously in thigh. Blood was
immediately removed by intracardiac puncture. Serum was
frozen at −80∘C for further analysis after blood clotting and
8000 g centrifugation. Tumors were harvested and kept for
analysis. Tumor tissues were divided into two equal parts,
frozen in liquid nitrogen or fixed in a 10% formaldehyde
solution, and embedded in paraffin.
2.3. Immunofluorescence (IF). Blocking has been performed
with immunofluorescence buffer (PBS, 3% BSA, 0.2% Triton
100x) for 1 h followed by 15min incubation with a second
immunofluorescence buffer (PBS, 1% BSA, 0.06% Triton
100x). Primary antibody against AT1R (1 : 100, Rabbit, (N-10):
sc-1173, Santa-Cruz Biotechnology, USA) has been incubated
for 2 h at room temperature in a humidified chamber. After
washing, cells have been incubated with Alexa-Fluor 546
goat anti-Rabbit Ig G (H + L), (1 : 5000, Molecular Probes,
USA) for 2 hours. The nuclei were counterstained with
DAPI/Antifade (Q-Biogene,MPBiomedicals, USA). Samples
were analyzed with fluorescence microscope system (LEICA
DMRXA, Germany).
2.4. Histology and Immunochemistry (IHC). Histological
examination was performed on 5 𝜇m formalin-fixed paraffin
sections stained with hematoxylin and eosin safran. All
specimens have been examined blindly by a single pathologist
(NRL).
The IHC experiments were realized on 5 𝜇m tumour
sections which were incubated at room temperature for 1 h
with primary antibodies against KI67 (1 : 100, monoclonal
rabbit antibody, clone SP6, Interchim, France), CD31 (1 : 50,
rat monoclonal antibody, clone SZ 31, Dianova, Germany),
and VEGF-A (1 : 100, rabbit polyclonal antibody, clone Ab-
4, Calbiochem, USA). Immunostaining was performed using
BenchMark XT-Ventana Medical Systems with kit DABMAP
(using streptavidin/biotin system) for CD31 or kit OMN-
IMAP (system “biotin-free” using multimer technology) for
KI67 and VEGF with antigen retrieval for all (citrate buffer
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pH 6.0; Tris/Borate/EDTA pH 8.0). In order to detect apop-
totic cells, tumors were stained with antiactivated caspase-3
primary antibody (1 : 500, monoclonal mouse antibody, clone
3G2, Cell Signaling Technology, USA). Tissues have been
blocked for 15min and then incubatedwith primary antibody
overnight at 4∘C, and the incubation with the secondary
antibody conjugated to horseradish peroxidase (Envision +
Dual Link System-HRP, Dako, Denmark). Revelation was
performed with the diaminobenzidine chromogen (Dako,
Denmark). Negative controls were performed by omitting
the primary antibody. Immunoreactivity of VEGF-A, KI67,
and activated caspase-3 was expressed as the percentage of
positive cells by scoring 500 cells. MicroVascular Density
(MVD), expressed as the number of vessel sections per
mm2, was determined by analyses of 10 representative fields
accounting for 2mm2. To perform the analysis of tumor
necrosis, glass slides were converted to digital slides with the
scanner Nanozoomer 2.0-RS Hamamatsu. We used the NDP
viewer Hamamatsu to determine the percentage of necrosis
bymeasurement of tumor area and necrosis, respectively.The
way is to draw a freehand region around the tissue of interest
to obtain an automatic area measurement.
2.5. Measurement of VEGF by ELISA. VEGF concentrations
of the murine serum were determined by ELISA method in
accordancewith supplier’s instructions (Quantikine kit, RnD,
USA).
2.6. Western Blot Analysis. Protein extracts were prepared
from frozen tumor tissues. Thin cuts of tissues were done
before homogenisation in mRIPA buffer (50mM Tris-HCl,
pH 7.4, 1% NP-40, 0.5% sodium deoxycholate, 150mM
sodium chloride, 1mM EDTA, 1mM sodium fluoride,
1mM AEBSF, 10 𝜇g/mL aprotinin, 10 𝜇g/mL leupeptin, and
1mM sodium orthovanadate). Extracts were centrifuged at
10,000 rpm for 10min and centrifuged during 30min at
4∘C. Fifty 𝜇g of each extract was electrophoresed on a
15% polyacrylamide gel and transferred onto nitrocellulose
membranes. The membranes washed with TBST (50mM
Tris-HCl, pH 7.5, 150mM NaCl, 0.05% Tween-20) have been
saturated with 5% low fat milk in TBST for 2 h at room
temperature and then incubated with primary antibodies
in 2.5% low fat milk in TBST at 4∘C overnight, followed
by an incubation with horseradish peroxidase conjugated
anti-rabbit or anti-mouse IgG antibodies (1 : 50 000 in TBST-
BSA2.5% for 1 h at RT). All the protein extracts were frozen
at −80∘C before blotting.
Antibodies against p44/42MAP kinase (Erk1/2) (1 : 2000,
polyclonal rabbit antibody, Cell Signaling, USA), phospho-
p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (1 : 1000, mono-
clonal mouse antibody, E10 clone, Cell Signaling, USA),
AKT (1 : 500, polyclonal rabbit antibody, 9272, Cell Signaling,
USA), phospho-AKT (Ser 473) (1 : 1000, polyclonal rab-
bit antibody, Cell Signalling), phospho-VEGFR2/KDR/flk-1
(Y1214) (1 : 1000, polyclonal rabbit antibody, RnD Systems,
USA), and PARP (1 : 500, monoclonal rabbit antibody, 46D11
clone, Cell Signaling, USA) were incubated overnight at
4∘C, and then horseradish peroxidase-conjugated secondary
antibodies (1 : 10000, Jackson Immuno-Research laboratories,
Baltimore,MD) that specifically bind to the primary antibody
were used. The blots were then disclosed with a chemilumi-
nescent detection system (SuperSignal West Dura Extended
Duration Substrate, Pierce Biotechnology, USA) which can
be visualised on X-ray film (Tabletop processor, CURIX 60,
AGFA HealthCare, Belgium).
2.7. MTT Assay for Cell Viability. The effect of the sunitinib,
telmisartan, or combined association on cell proliferation
was assayed in sterile 96-well microtiter tissue plates (Becton
Dickinson, Oxnard, USA). The 786-O cells were seeded
at 2.5 × 104 cells/mL of medium (100 𝜇L per well). The
different compounds (10𝜇L per well) at the appropriate
concentration (10 nM–1mM) were added after 24 hours of
cell culture. Incubations were performed at 37∘C during
72 h. After exposure to the compounds, cell growth was
determined by measuring the formazan formation from
3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium (MTT).
Multiskan MCC/340 microplate reader (Labsystems, Israel)
was used for absorbance measurements (570 nm). Viability
was determined by calculation of the ratio of optical density
at 𝐽3/𝐽0.
2.8. Statistical Analysis. Data are expressed as median. Com-
parison of continuous variables used nonparametric Kruskal-
Wallis or Wilcoxon tests. For tumor growth, all individual
data were analyzed simultaneously using nonlinear mixed
effect models, which allow sharing information across sub-
jects. Correlation between continuous variables was assessed
by Spearman correlation. A probability (P) value of less than
0.05 was considered statistically significant for overall inter-
group comparisons and two-by-two comparisons. Analyses
were performed with SAS software version 9.2 (SAS Institute,
USA).
3. Results
3.1. Cell Lines Express Angiotensin Type-1 Receptor. The
expression of AT1R was revealed by Western Blot on 786-O
cells and tumor tissues treated or not with sunitinib alone,
telmisartan alone, or combination (Figure 1(a)).The presence
of the receptor AT1-R was visualised onto the cell line 786-O
cells by immunofluorescence (Figure 1(b)).
3.2. Mice and Tumor Development. Ten mice were treated in
each group. Two animals died in the control group before
the beginning of treatment. One mouse that belongs to the
sunitinib group developed severe side effects as oedema,
hypertension, and hepatomegaly and died 10 days after the
beginning of treatment. Nevertheless, its tumor was har-
vested and analyzed. In addition, one mouse corresponding
to the group treated with telmisartan did not develop any
tumour. Consequently, 3 tumours were missing for the
analysis.
During the follow-up, mice treated with sunitinib alone
developed hypertension. Medium arterial pressure in the
sunitinib group, 100.7 ± 21.8mmHg, was significantly differ-
ent from blood pressure in other groups, 85.3 ± 18.0mmHg
in control group, 77.0 ± 18.2mmHg in the telmisartan group,
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Figure 1: (a) Western Blot analysis of AT1R expression in 786-O cells and in different mice treated by either DMSO, sunitinib, telmisartan,
or combined drugs. (b) Immunostaining of AT1R (red) and DAPI staining (blue) in 786-O cells. AT1-R stains for the membranes of tumour
and endothelial cells (×1000).
and 70.8 ± 1.9mmHg in the association group (𝑃 = 0.0034,
Kruskal-Wallis test). These results confirm that drugs orally
administered were well assimilated by animals leading to
expected systemic effects on blood pressure.
Using a statistical kinetic model, tumors tended to grow
slower in the combination group compared to other groups
(𝑃 = 0.06) (Figures 2(a) and 2(b)—see Supplementary Data
available online at http://dx.doi.org/10.1155/2014/901371).
3.3. Combination of Telmisartan with Sunitinib Increases
Tumour Necrosis. The histological analysis of tumors
induced in mice revealed in all cases the development of
a Fuhrman 4 ccRCC (Figure 3(a)(A)). HES staining also
revealed the presence of necrosis area which was significantly
more extensive whenmice were treated with the combination
of telmisartan and sunitinib (𝑃 = 0.038, Figures 3(a)(B) and
3(a)(C)). Indeed, necrosis in the combination group (16.9%
± 12.8%) was significantly more important compared to the
control group (4.7% ± 3.4%—𝑃 = 0.0185), the sunitinib
group (6.7% ± 4.1%—𝑃 = 0.0376), or the telmisartan group
(6.7% ± 4.1%—𝑃 = 0.0373). As a consequence, the quantity
of viable tumour decreased in the combination group
compared to the others (𝑃 < 0.0001).
3.4. Combination Inhibits Neovascularisation. As tumour
necrosis increased in mice treated with the combination of
drugs, we investigated tumour vascularisation.Microvascular
density (MVD) was determined by CD31 staining for each
tumour (Figure 4(a)). Drugs combined globally decreased
MVD in the centre of tumors (MVD = 3.8 vessels/mm2±
2.4—𝑃 = 0.0038) as well as compared to control group (10.6
± 5.6 vessels/mm2—𝑃 = 0.0029), sunitinib group (7.7 ±
3.6 vessels/mm2—𝑃 = 0.0171), and telmisartan group (9.7
± 4.2 vessels/mm2—𝑃 = 0.0036) (Figure 4(b)). It was also
observed that tumors with low MVD had more extensive
necrosis (Spearman correlation coefficient is 0.45—𝑃 =
0.005). In contrast to central vasculature, peripheral vascu-
lature was not affected by drug regimen administered.
3.5. Combination Decreases VEGF-A Concentration in Mice
Serum. As the drug administration affected tumor vascu-
larisation, we wondered whether the concentration of cir-
culating VEGF-A was altered. We evaluated the circulating
VEGF-A concentration by ELISA. The amount of VEGF-A
significantly increased in the sunitinib group (10022 pg/mL
± 12741 pg/mL) compared to the control group (1010 pg/mL
± 606 pg/mL—𝑃 = 0.0045), whereas there was no sig-
nificant difference with the telmisartan group (1172 pg/mL
± 1122 pg/mL—𝑃 = 1.00). When telmisartan was used in
combination, the upraise of seric VEGF-A concentration
induced by sunitinibwas lower but not statistically significant
(2117 pg/mL ± 825 pg/mL—𝑃 = 0.141, Figure 4(c)).
3.6. Combination Does Not Modify Tumour Proliferation or
Apoptosis . The effect of combination of telmisartan and
sunitinib was first tested on 786-0 cell culture by MTT assay.
The association did not modify the effect of sunitinib alone
on cell proliferation (Figure 5(a)). Moreover, no variation of
the ratio ERK1/2/P-ERK or AKT/p-AKTwas registered in the
assay (Figure 5(b)). The results indicate that association was
not more toxic on 786-O cells than sunitinib alone.
Telmisartan as well as sunitinib is known to inhibit
tumor cell proliferation and induce apoptosis on several
tumours. The combination of sunitinib and telmisartan did
not inhibit tumor cell proliferation, as well as each of them
separately. The percentage of proliferative cells stained by
KI67was analyzed for each group and exhibited a high degree
of expression: from 59% to 64% (p = ns—Figure 6(a)).
The expression of proteins involved in the proliferation
and survival pathways was also analyzed by Western Blot
(Figure 6(b)). Neither activated ERK pathway nor activated
AKT pathway was modified in the case of treatment with the
combination of telmisartan and sunitinib.
4. Discussion
In this work, we have shown that telmisartan potentiates
the effects of sunitinib on renal cell carcinoma by increasing
tumor necrosis. AT1-R blockers are widely used drugs. Sev-
eral years ago, there have been many clinical trials on car-
diovascular and renal endpoints, and no increased incidence
of cancer has been usually reported as secondary endpoint
or in post hoc analysis [15]. Despite those trials and many
scientific studies on different types of cancers, there is still
a controversy regarding antitumoral or protumoral effects of
these treatments [16].
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Figure 2: (a) Kinetics of tumor growth separated in four groups with or without telmisartan (ARA2) and sunitinib (TKI). (b) Kinetic curves
with prolongation until 22 weeks of the four groups with or without telmisartan (ARA2) and sunitinib (TKI).
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Figure 3: Combination significantly increases tumor necrosis but not sunitinib alone. (a) Histological analysis of tumors by HES staining
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Similar combinations of RAS blockers with classical
anticancer therapies have already been studied in other
murine models [17–20]. These previous works highlighted
the antiangiogenic properties or antiproliferative effects of
the associated compounds. Sunitinib was developed to target
angiogenesis [21] and AT1-R blockers are well known to
decrease angiogenesis in numerous experimental studies [22,
23]. Because of the same therapeutical target, this combina-
tion could be seen as redundant but might be beneficial for
several reasons. The experimental and clinical studies clearly
showed that sunitinib mainly acts by inhibiting VEGFR2
activation on endothelial cells [21] which triggers a negative
feedback in tumours leading to a VEGF-A oversecretion [24].
Moreover, AT1-R blockers have been described to inhibit
VEGF-A secretion by tumour cells [25] and decrease tumor
angiogenesis [22, 26] as well as tumour cell proliferation [27].
AT1-R antagonists could also trigger cancer cell apoptosis
[28]. RAS blockers have been studied in many types of
cancers, principally prostate, breast, and pancreas, but rarely
in ccRCC. Though renal tumors are highly vascularised
and could represent one novel target for RAS blockers,
only one murine model described that ACE-Is prevent the
development of distant metastasis [14].
Some authors clearly showed synergistic association
between classical antitumour treatments and AT1-R antag-
onists or ACE-Is. For example, ACE-Is use increases effects
of radiotherapy for the treatment of lung cancer [17]. Similar
benefits are obtained in hepatocarcinoma by the association
of ACE-Is and 5-fluorouracil [18] or interferon-𝛽 [19]. AT1-
R blockers also improve the efficiency of gemcitabine on
pancreatic tumour growth [20]. Based on these data, class
effect of antiangiogenesis of angiotensin receptor blockers
remains possible.
This multiple step blockage of VEGF pathway leads to the
decrease of central neovascularisation and to the increased
necrosis observed in our model. Nevertheless, our model
does not show any additive effects on proliferation or apopto-
sis contrary to results of experimental works in other tumor
models [28]. It can be suggested that tumors induced by 786-0
cell injection developedmolecular mechanisms which confer
a resistance against antiproliferative drug regimen. These
findings might not be the same in other ccRCC xenograft
models and have to be further explored with primary cell
lines.
The clinical use of the combination of telmisartan and
sunitinib is yet to be determined. In a previous study, we
demonstrated that renal cell carcinomas differently express
AT1-R with a high expression level of AT1-R in the most
aggressive tumors [11]. As described in breast cancer for
estrogen receptors [29], it can be expected that tumors that
highly express AT1-R will be more sensitive to telmisartan.
This hypothesis needs to be confirmed. In addition, some
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Figure 4: Sunitinib in combination with telmisartan significantly decreases central MVD and tends to decrease seric VEGF-A concentration.
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sunitinib toxicity alone or combined with telmisartan by MTT in 786-O cell culture. (b) Western Blot of ERK pathway and AKT pathway in
786-O cell culture.
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Figure 6: The use of sunitinib and/or telmisartan does not change tumor proliferation or phosphorylation of ERK and AKT. (a) Tumor
analysis by Ki67 staining (×200) in control tumor and after treatment with sunitinib alone, telmisartan alone, and in combination. No
difference between groups is observed. (b) Analysis of proteins ERK1/2, AkT, p-ERK1/2, and p-AKT from tumor control and treated group.
clinical retrospective studies have beenperformedonpatients
with cancer receiving RAS blockers for hypertension. Among
127 patients presenting metastatic renal cell carcinoma and
treated with sunitinib, the use of ACE-I or AT1-R blockers
significantly improved response to treatment and overall
survival [30]. The survival of patients with a non-small-cell
lung cancer also improves when they receive ACE-I or AT1-
R blockers to treat hypertension [31]. The risk of recurrence
was also reduced in breast cancer by the use of AT1-R blockers
[32]. Prospective study with RAS blockers in addition to anti-
VEGF therapies is now warranted.
5. Conclusion
Our study demonstrated that telmisartan potentiated antian-
giogenic effects of sunitinib in a murine model of xenograft.
Combination decreased neovascularisation in the center of
the tumor and induced more tumor necrosis. These could
be the result of a multiple targeting of different pathways on
endothelial cells as well as on tumor cells. Such results must
be now confirmed in clinical prospective studies.
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